Policy & Regulation
GSK hepatitis B therapy bepirovirsen gains FDA priority review and breakthrough designation
28 April 2026 - Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) announced on Tuesday that the US Food and Drug Administration (FDA) has accepted its New Drug Application for bepirovirsen for pr...
Boehringer Ingelheim's survodutide phase 3 data show significant weight loss in obesity trial
28 April 2026 - Danish biotechnology company Zealand Pharma A/S (CPH:ZEAL) reported on Tuesday that pharmaceutical company Boehringer Ingelheim has achieved positive Phase 3 results for survodutide, a...
Johnson & Johnson IMAAVY (nipocalimab-aahu) granted FDA Priority Review as potential treatment for wAIHA
28 April 2026 - US healthcare company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Monday that the US Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biol...
Lilly agrees to acquire Ajax Therapeutics
28 April 2026 - US pharmaceutical company Eli Lilly and Company (NYSE:LLY) and Ajax Therapeutics Inc, a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproli...
Novartis secures European approval for remibrutinib in chronic spontaneous urticaria
...
GSK secures US and EU fast-track designations for efimosfermin in MASH
27 April 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) announced on Monday that it has received Breakthrough Therapy Designation from the US Food and Drug Administration, as well as ...